Verge has pioneered the industry's most advanced all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale for the biggest medical challenges of our time.
Verge was born from the convergence of multiple technological forces, including human genomics, machine learning, biological engineering, and translational medicine, that are enabling us to decipher biology. Instead of using animal or cell models, we have built one of the world's largest proprietary multi-omics databases directly from human tissue. We use machine learning to map the complex causes of disease and develop those insights into proprietary drug candidates on our internal biology and chemistry platforms.
Our first drug VRG50635, a small molecule inhibitor of PIKfyve, has entered the clinic for amyotrophic lateral sclerosis (ALS). It was discovered by CONVERGE®, Verge’s all-in-human, AI-powered platform, moving from research to clinic in just four years. We are working on a dozen breakthrough opportunities on Parkinson's Disease, Frontotemporal Dementia, and other devastating diseases with no effective treatments to date.
